Increased Insulin Resistance in Hepatitis-C Infection—Association with Altered Hepatic Function Testing
Abstract
:1. Introduction
2. Methods and Materials
3. Statistical Analysis
4. Results
5. Discussion
6. Limitations
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Averhoff, F.M.; Glass, N.; Holtzman, D. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin. Infect. Dis. 2012, 55 (Suppl. S1), S10–S15. [Google Scholar] [CrossRef]
- Cooke, G.S.; Lemoine, M.; Thursz, M.; Gore, C.; Swan, T.; Kamarulzaman, A.; DuCros, P.; Ford, N. Viral hepatitis and the Global Burden of Disease: A need to regroup. J. Viral Hepat. 2013, 20, 600–601. [Google Scholar] [CrossRef] [PubMed]
- Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57, 1333–1342. [Google Scholar] [CrossRef] [PubMed]
- Dhingra, A.; Kapoor, S.; Alqahtani, S.A. Recent advances in the treatment of hepatitis C. Discov. Med. 2014, 18, 203–208. [Google Scholar]
- Lauer, G.M.; Walker, B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41–52. [Google Scholar] [CrossRef] [PubMed]
- Yoneda, M.; Saito, S.; Ikeda, T.; Fujita, K.; Mawatari, H.; Kirikoshi, H.; Inamori, M.; Nozaki, Y.; Akiyama, T.; Takahashi, H.; et al. Hepatitis C virus directly associated with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J. Viral Hepat. 2007, 14, 600–607. [Google Scholar] [CrossRef] [PubMed]
- Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 2010, 50, 1387–1396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Negro, F.; Alaei, M. Hepatitis C virus and type 2 diabetes. World J. Gastroenterol. 2009, 15, 1537–1547. [Google Scholar] [CrossRef]
- Kaddai, V.; Negro, F. Current understanding of insulin resistance in hepatitis C. Expert Rev. Gastroenterol. Hepatol. 2011, 5, 503–516. [Google Scholar] [CrossRef]
- White, D.L.; Ratziu, V.; El-Serag, H.B. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J. Hepatol. 2008, 49, 831–844. [Google Scholar] [CrossRef] [Green Version]
- Bose, S.K.; Ray, R. Hepatitis C virus infection and insulin resistance. World J. Diabetes 2014, 5, 52–58. [Google Scholar] [CrossRef]
- El-Zayadi, A.R.; Anis, M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J. Gastroenterol. WJG 2012, 18, 212. [Google Scholar] [CrossRef]
- Kawaguchi, T.; Sata, M. Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization. World J. Gastroenterol. 2010, 16, 1943–1952. [Google Scholar] [CrossRef] [Green Version]
- Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J. Endocrinol. Metab. 2018, 22, 421–428. [Google Scholar] [CrossRef]
- Rodionova, S.V.; Zvenigorodskaya, L.A.; Biryukova, E.V. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Cons. Med. 2016, 18, 46–50. [Google Scholar] [CrossRef]
- Karami, E.; Khaledan, A.; Ahanghar, H.; HOJJAT, S. The effect of an endurance training period on plasma alanine aminotransferase level in patients with nonalcoholic fatty liver disease. J. Anim. Physiol. Dev. 2013, 6, 33–39. [Google Scholar]
- Petit, J.M.; Bour, J.B.; Galland-Jos, C.; Minello, A.; Verges, B.; Guiguet, M.; Brun, J.M.; Hillon, P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J. Hepatol. 2001, 35, 279–283. [Google Scholar] [CrossRef]
- Campo, J.A.D.; Romero-Gómez, M. Steatosis and insulin resistance in hepatitis C: A way out for the virus? World J. Gastroenterol. 2009, 15, 5014–5019. [Google Scholar] [CrossRef]
- Narita, R.; Abe, S.; Kihara, Y.; Akiyama, T.; Tabaru, A.; Otsuki, M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J. Hepatol. 2004, 41, 132–138. [Google Scholar] [CrossRef]
- Nakamura, M.; Kanda, T.; Nakamoto, S.; Miyamura, T.; Jiang, X.; Wu, S.; Yokosuka, O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS ONE 2013, 8, e81312. [Google Scholar] [CrossRef]
- Ray, S.; Talukdar, A.; Sonthalia, N.; Saha, M.; Kundu, S.; Khanra, D.; Guha, S.; Basu, A.K.; Mukherjee, A.; Ray, D.; et al. Serum lipoprotein ratios as markers of insulin resistance: A study among non-diabetic acute coronary syndrome patients with impaired fasting glucose. Indian J. Med. Res. 2015, 141, 62–67. [Google Scholar]
- Laloo, D.; Walke, P.; Bhimo, T.; Prasad, L.; Ranabir, S. Seroprevalence of hepatitis C infection in type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2015, 19, 296–299. [Google Scholar] [PubMed]
- Hum, J.; Jou, J.H. The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus. Clin. Liver Dis. 2018, 11, 73–76. [Google Scholar] [CrossRef]
- Naing, C.; Mak, J.W.; Ahmed, S.I.; Maung, M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: A meta-analysis. World J. Gastroenterol. 2012, 18, 1642–1651. [Google Scholar] [CrossRef] [PubMed]
- Mohammed, M.K.; Esmat, G.; Said, M.; Abdel Hamid, M.; Hassany, M.; Hassanein, M.A.; El-Atrebi, K.A.; El Gazzar, H.; Omar, M.S. Relationship between HCV infection and Insulin resistance in non-obese non-diabetic patients. Egypt. J. Hosp. Med. 2010, 41, 540–550. [Google Scholar] [CrossRef]
- Wang, L.-F.; Wu, C.-H.; Shan, Y.; Fan, X.-H.; Huo, N.; Lu, H.-Y.; Xu, X.Y. Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China. Chin. Med. J. 2011, 124, 183–188. [Google Scholar] [PubMed]
- Hui, J.M.; Sud, A.; Farrell, G.C.; Bandara, P.; Byth, K.; Kench, J.G.; McCaughan, G.W.; George, J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 25, 1695–1704. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.; Jinjuvadia, R.; Patel, R.; Liangpunsakul, S. Insulin Resistance is Associated with Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis. J. Clin. Gastroenterol. 2016, 50, 80–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phillips, H.; Balart, L.A. Problems with NASH? HAIR is some help: Dixon JB, Bhathal PS, O’Brien PE, Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese, Gastroenterology 2001;121:91–100. Am J. Gastroenterol. 2003, 98, 500–503. [Google Scholar]
- Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793–1801. [Google Scholar] [CrossRef]
- Cerf, M.E. Beta cell dysfunction and insulin resistance. Front. Endocrinol. 2013, 4, 37. [Google Scholar] [CrossRef] [Green Version]
- Samuel, V.T.; Shulman, G.I. Mechanisms for insulin resistance: Common threads and missing links. Cell 2012, 148, 852–871. [Google Scholar] [CrossRef] [Green Version]
- Escobar, E. Hypertension and coronary heart disease. J. Hum. Hypertens. 2002, 16 (Suppl. S1), S61–S63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Borrayo, G.; Basurto, L.; González-Escudero, E.; Diaz, A.; Vázquez, A.; Sánchez, L.; Hernández-González, G.O.; Barrera, S.; Degollado, J.A.; Córdova, N.; et al. TG/HDL-C ratio as cardio-metabolic biomarker even in normal weight women. Acta Endocrinol. 2018, 14, 261–267. [Google Scholar] [CrossRef]
- Felmlee, D.J.; Hafirassou, M.L.; Lefevre, M.; Baumert, T.F.; Schuster, C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013, 5, 1292–1324. [Google Scholar] [CrossRef] [Green Version]
Group A | Group B | p-Value | |||
---|---|---|---|---|---|
Mean | SD | Mean | SD | ||
Age in years | 55.65 | 7.13 | 56.01 | 7.51 | 0.71 |
BMI in kg/m2 | 29.43 | 1.76 | 24.22 | 1.91 | <0.001 |
Waist circumference in centimetres | 99.05 | 6.86 | 95.05 | 7.92 | 0.05 |
Systolic blood pressure | 146.62 | 14.60 | 129.5 | 11.1 | 0.05 |
Diastolic blood pressure | 92.76 | 8.57 | 86.01 | 7.85 | 0.05 |
Duration of diabetes mellitus in years | 4.40 | 3.51 | 4.2 | 3.40 | 0.772 |
Group A | Group B | p-Value | ||||
---|---|---|---|---|---|---|
Mean | SD | Mean | SD | |||
Hemogram | Haemoglobin gm% | 13.90 | 0.95 | 14.01 | 1.01 | 0.61 |
Total count | 8283.82 | 471.79 | 7912.11 | 419.2 | 0.001 | |
MCV | 94.40 | 3.96 | 92.01 | 4.01 | 0.012 | |
MCHC | 31.50 | 5.30 | 32.5 | 5.9 | 0.18 | |
Blood glucose | Fasting blood glucose in mg/dL | 148.69 | 34.19 | 151.11 | 36.35 | 0.66 |
Post prandial blood glucose in mg/dl | 230.21 | 64.33 | 250.01 | 66.29 | 0.12 | |
Lipid profile | Total cholesterol in mg/dL | 209.82 | 45.08 | 199.1 | 35.85 | 0.19 |
Triglyceride in mg/dL | 161.86 | 27.11 | 159.56 | 30.17 | 0.72 | |
HDL cholesterol in mg/dL | 38.87 | 5.69 | 40.95 | 6.01 | 0.05 * | |
Triglyceride/HDL ratio | 4.16 | 1.23 | 3.9 | 1.07 | 0.05 * | |
LDL cholesterol in mg/dL | 128.59 | 32.52 | 130.24 | 30.43 | 0.74 | |
Liver Function test | Total protein | 6.52 | 1.58 | 7.01 | 1.34 | 0.05 * |
Albumin | 3.1 | 1.01 | 3.98 | 0.91 | 0.05 * | |
Total bilirubin | 1.9 | 0.58 | 0.8 | 0.34 | 0.05 * | |
Direct bilirubin | 0.65 | 0.21 | 0.21 | 0.09 | 0.05 * | |
Indirect bilirubin | 1.25 | 0.89 | 0.59 | 0.22 | 0.05 * | |
AST | 41 | 5.68 | 28 | 2.98 | 0.05 * | |
ALT | 49 | 6.45 | 26 | 2.55 | 0.05 * | |
Renal Function test | Urea in mg/dL | 32.38 | 9.110 | 33.01 | 5.91 | 0.68 |
Creatinine in mg/dL | 1.0343 | 0.32381 | 0.98 | 0.21 | 0.357 |
Group A | Group B | p-Value | |||
---|---|---|---|---|---|
Mean | SD | Mean | SD | ||
Ferritin in ng/mL | 324.04 | 53.112 | 162.17 | 42.01 | 0.001 |
Insulin | 4.91 | 2.29 | 3.87 | 2.07 | 0.02 |
Insulin resistance | 5.91 | 1.21 | 3.55 | 1.17 | 0.001 |
Glycated Hemoglobin (HbA1c) | Insulin | Insulin Resistance | Ferritin | ||
---|---|---|---|---|---|
Glycated hemoglobin (HbA1c) | r | 1 | −0.130 | 0.094 | −0.185 |
Sig | 0.192 | 0.350 | 0.063 | ||
Insulin | r | −0.130 | 1 | 0.960 ** | 0.546 ** |
Sig | 0.192 | 0.000 | 0.000 | ||
Insulin resistance | r | 0.094 | 0.960 ** | 1 | 0.512 ** |
Sig | 0.350 | 0.000 | 0.000 | ||
Ferritin | r | −0.185 | 0.546 ** | 0.512 ** | 1 |
Sig | 0.063 | 0.000 | 0.000 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mishra, P.R.; Bharti, A.; Arora, R.; Mir, I.A.; Punia, V.P.S. Increased Insulin Resistance in Hepatitis-C Infection—Association with Altered Hepatic Function Testing. Pathophysiology 2022, 29, 326-332. https://doi.org/10.3390/pathophysiology29030024
Mishra PR, Bharti A, Arora R, Mir IA, Punia VPS. Increased Insulin Resistance in Hepatitis-C Infection—Association with Altered Hepatic Function Testing. Pathophysiology. 2022; 29(3):326-332. https://doi.org/10.3390/pathophysiology29030024
Chicago/Turabian StyleMishra, Praveen Raman, Akash Bharti, Ridhi Arora, Irfan Ahmad Mir, and V. P. S. Punia. 2022. "Increased Insulin Resistance in Hepatitis-C Infection—Association with Altered Hepatic Function Testing" Pathophysiology 29, no. 3: 326-332. https://doi.org/10.3390/pathophysiology29030024
APA StyleMishra, P. R., Bharti, A., Arora, R., Mir, I. A., & Punia, V. P. S. (2022). Increased Insulin Resistance in Hepatitis-C Infection—Association with Altered Hepatic Function Testing. Pathophysiology, 29(3), 326-332. https://doi.org/10.3390/pathophysiology29030024